首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1493594

肿瘤药物市场 - 全球产业规模、份额、趋势、机会和预测，按药物类别、给药途径、配销通路、地区和竞争细分，2019-2029F

Oncology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route of Administration, By Distribution Channel, By Region and Competition, 2019-2029F

出版日期: 2024年05月15日 | 出版商:

TechSci Research | 英文 184 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2023年全球肿瘤药物市场价值为2,206.7亿美元，预计在预测期内将稳定成长，到2029年复合年增长率为13.21%。细胞生长引起的。癌症死亡率不断上升，加上人口成长，给个人、家庭和全球医疗保健系统带来了巨大的身体和经济负担。根据疾病的类型和阶段，采用手术、肿瘤药物、放射治疗、免疫疗法和一系列其他治疗方法来治疗癌症。医生可能会开立特定药物来阻碍癌细胞的新陈代谢或破坏其 DNA。在全球对抗癌症的努力中，不同类型的药物被用于治疗不同类型的癌症。癌症药物用于治疗、消除、控制和预防癌细胞扩散到其他器官和组织。它们与肿瘤药物、免疫疗法、放射疗法和其他治疗方案相结合。它们可以缓解疼痛、皮疹和噁心等症状。治疗所需的特定类型或类别的药物取决于癌症的类型和阶段等因素，以及与其他药物合併使用时的潜在副作用。几种恶性生长药物已获得 FDA 批准，并被肿瘤学家广泛使用。随着癌症患者数量的不断增加，全球对癌症药物的需求也增加。

市场概况
预测期	2025-2029
2023 年市场规模	2206.7亿美元
2029 年市场规模	4626.6亿美元
2024-2029 年复合年增长率	13.21%
成长最快的细分市场	标靶药物
最大的市场	北美洲

主要市场驱动因素

新癌症药物和治疗方法的广泛研究和开发

癌症盛行率增加

增加医疗基础建设投资

对先进抗癌药物的需求增加

主要市场挑战

抗癌药物的不良反应

与肿瘤药物相关的高成本

主要市场趋势

创新技术开发

新兴地区越来越多地采用和偏好标靶治疗

细分市场洞察

药品类别见解

管理途径见解

区域洞察

Global Oncology Drugs Market was valued at USD 220.67 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 13.21% through 2029. A multitude of diseases, including cancer, arise from abnormal cell growth in various organs or tissues. The increasing mortality rate from cancer, coupled with population growth, places a significant physical and financial burden on individuals, families, and the global healthcare system. Surgery, oncology drugs, radiation therapy, immunotherapy, and a range of other treatments are employed in the management of cancer, depending on the type and stage of the disease. Physicians may prescribe specific medications aimed at impeding the metabolism of cancer cells or damaging their DNA. In the global effort to combat cancer, diverse drug classes are utilized for various types of cancer. Cancer medications are utilized to treat, eliminate, manage, and prevent the spread of cancer cells to other organs and tissues. They are combined with oncology drugs, immunotherapy, radiation therapy, and other treatment options. They can alleviate symptoms such as pain, rashes, and nausea. The specific type or class of medication required for treatment depends on factors such as the type and stage of cancer, as well as the potential side effects when combined with other drugs. Several malignant growth drugs have received FDA approval and are widely used by oncologists. The global demand for cancer medications is increasing in response to the growing number of cancer patients.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 220.67 Billion
Market Size 2029	USD 462.66 Billion
CAGR 2024-2029	13.21%
Fastest Growing Segment	Targeted Drugs
Largest Market	North America

Key Market Drivers

Extensive Research and Development into New Cancer Drugs and Treatments

Extensive research and development (R&D) efforts into new cancer drugs and treatments are poised to drive a significant increase in the demand for oncology drugs. The relentless pursuit of more effective therapies and a deeper understanding of cancer biology has resulted in a robust pipeline of promising oncological innovations, which are set to transform the landscape of cancer care in the future. As researchers unravel the genetic and molecular intricacies of various cancer types, they identify specific vulnerabilities that can be exploited for treatment. Precision medicine, which tailors' therapies based on the individual patient's genetic profile, is gaining prominence, driving the demand for targeted therapies and companion diagnostics. These therapies offer higher efficacy and reduced side effects compared to traditional treatments, making them highly sought after.

Immunotherapy has emerged as a groundbreaking approach in oncology. Checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines are among the innovative immunotherapies that have demonstrated remarkable success in treating some of the most challenging malignancies. The ongoing research and development in this field, including efforts to expand the applicability of immunotherapies to a broader range of cancers, are expected to significantly boost demand for these treatments. The extensive research and development into new cancer drugs and treatments are propelling the oncology drug market into an era of unprecedented growth. With a focus on precision medicine, immunotherapy, and the expanding understanding of cancer biology, the demand for oncology drugs is set to surge as patients and healthcare providers seek more effective and tailored therapies to combat this complex and multifaceted disease.

Increasing Prevalence of Cancer

The rising prevalence of cancer is estimated to significantly enhance the growth rate of the oncology drugs drug market. According to the World Health Organization (WHO), cancer stands as the leading cause of mortality worldwide, responsible for approximately 10 million deaths in 2020 alone. This devastating disease accounts for nearly one in every six deaths globally, highlighting the urgent need for effective treatments. Shockingly, it is not just adults who are affected by cancer. Around 400,000 children are diagnosed with this debilitating illness every year, emphasizing the alarming impact on younger populations.

The burden of cancer on society is further underscored by the fact that cervical cancer, a form of cancer that affects the cervix, holds the unfortunate distinction of being the most frequent cancer in 23 countries across the globe. In the battle against cancer, oncology drugs has emerged as the most common treatment modality. It often serves as a vital component, working in conjunction with other cancer treatments to combat the disease. Specifically, neo-adjuvant oncology drugs, administered before surgery and radiation therapy, aims to shrink tumor cells, while adjuvant oncology drugs, given after surgery or radiation therapy, works towards further reducing the tumor cell size. However, the fight against cancer is not without hope. Continuous advancements in oncology drugs and its integration with other treatment modalities offer promise and progress. Researchers and healthcare professionals are tirelessly working to improve the efficacy and minimize the side effects of oncology drugs, bringing us closer to a world where cancer can be treated effectively, and lives can be saved.

Increasing Investment for Healthcare Infrastructure

Another significant factor impacting the growth rate of the oncology drugs drug market is the increasing healthcare expenditure, which plays a vital role in enhancing the infrastructure required for effective treatment. With the continuous rise in healthcare spending, hospitals and healthcare facilities can invest in advanced technologies, state-of-the-art equipment, and highly skilled medical professionals. These investments contribute to the overall development of the healthcare infrastructure.

Various government organizations are actively working towards enhancing the healthcare infrastructure by allocating additional funding. This increased investment not only supports the expansion of healthcare facilities but also promotes research and development in the field of oncology drugs. Consequently, these market dynamics pave the way for innovation, improved patient care, and better treatment outcomes. In summary, the combined efforts of rising healthcare expenditure and government initiatives focused on improving the healthcare infrastructure are driving the growth of the oncology drugs drug market. These developments hold the promise of providing advanced treatment options and ensuring better healthcare services for patients in need.

Rise In Demand for Advanced Cancer Drugs

The rise in demand for advanced cancer drugs represents a compelling force that is expected to significantly boost the demand for oncology drugs in the healthcare industry. This surge in demand is fueled by several key factors, each contributing to the growing need for cutting-edge therapies in the fight against cancer. The evolving landscape of cancer care places a strong emphasis on precision medicine. As our understanding of cancer genetics and molecular pathways deepens, the demand for targeted therapies tailored to the genetic makeup of individual patients is on the rise. These advanced cancer drugs are designed to specifically target cancer cells while sparing healthy tissue, offering improved efficacy and reduced side effects compared to traditional treatments. The rise in demand for advanced cancer drugs reflects the evolving landscape of cancer care, emphasizing precision medicine, immunotherapy, and the pressing need for innovative treatments. This demand surge is expected to propel the oncology drug market forward, offering new hope to cancer patients and reshaping the future of cancer treatment.

Key Market Challenges

Adverse Effect of Anti-Cancer Drugs

Drugs used in oncology drugs are designed to target and eliminate rapidly dividing cells, a hallmark of cancer cells. However, their mechanism of action often leads to unintended consequences, as they cannot differentiate between healthy cells and cancerous cells. One of the most common adverse effects of anti-cancer drugs is the damage they cause to blood-forming cells in the bone marrow, potentially resulting in anemia and compromised immune function.

The impact of these medications extends beyond the hematological system. The hair follicles can become damaged, leading to hair loss, which can have a profound psychological impact on patients. Nausea, constipation, and fertility problems are additional serious side effects that can significantly affect the quality of life for individuals undergoing oncology drugs. In the case of head and neck cancer treatment, specific drugs can cause a range of side effects. These include rashes, itching, weight loss, mouth sores, and issues with the nerves and muscles, such as numbness, pain, and tingling sensations. These symptoms can further exacerbate the physical and emotional burden experienced by patients. Given these severe adverse effects, the development and progress of the global market for cancer medications face significant challenges. Efforts to improve treatment outcomes for cancer patients should not only focus on the efficacy of the drugs but also on minimizing the adverse effects that can impact their overall well-being.

High Cost Associated with the Oncology Drugs

The high cost associated with oncology drugs is expected to greatly hinder the growth rate of the market. The scarcity of skilled professionals and inadequate healthcare infrastructure in developing economies will pose significant challenges to the oncology drugs drug market. In addition to these challenges, the side effects of oncology drugs, such as heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, decreased lung, kidney, and liver quality, reduced bone density, and lack of awareness among people, will act as restraints and further impede the growth rate of the market during the forecast period. These factors collectively contribute to the complex landscape of the oncology drugs drug market and highlight the need for comprehensive strategies to address these obstacles.

Key Market Trends

Development of Innovative Technology

Oncology drugs, a crucial treatment in the battle against cancer, has greatly extended the lives of patients beyond what was previously possible. In the latest breakthrough in the field, scientists have developed a novel approach using customized nanoparticles to deliver cancer-fighting medications directly to affected areas, sparing healthy cells from harm. This cutting-edge method has demonstrated remarkable efficacy in eliminating malignant cells while preserving the integrity of surrounding healthy tissue. In order to precisely monitor the release, duration, and distribution of these medications, doctors employ advanced photon lasers that track the movement of these specially designed nanoparticles through the patient's body. Building upon these promising results, the University of California, Los Angeles, is currently conducting a clinical trial to further validate the effectiveness of this approach, particularly in the treatment of lower-stage cancer patients. With its potential to revolutionize cancer treatment, this innovative technique is poised to make a significant impact in the field of oncology drugs in the foreseeable future.

Growing Adoption and Preference for Targeted Therapy in Emerging Regions

The growing adoption and preference for targeted therapy in emerging regions represent a significant driver expected to boost the demand for oncology drugs. Targeted therapy has gained prominence in recent years due to its precision in treating cancer by specifically targeting cancer cells or their molecular pathways while minimizing damage to healthy cells.

Targeted therapy offers an effective and well-tolerated alternative to traditional chemotherapy, which often carries severe side effects. Patients in emerging regions, like anywhere else, seek therapies that improve their quality of life during treatment. Targeted drugs align with this preference by providing a more targeted and tolerable treatment experience. Advancements in diagnostic technologies, including molecular profiling and genetic testing, have become more accessible in emerging regions. These tools enable healthcare providers to identify specific genetic mutations or biomarkers driving a patient's cancer, facilitating the selection of the most appropriate targeted therapy. As diagnostic capabilities expand, the demand for corresponding targeted drugs increases. Increasing investment in healthcare infrastructure, research, and pharmaceutical markets in emerging regions contributes to greater access to advanced oncology drugs, including targeted therapies. This growing accessibility, coupled with healthcare professionals' awareness and expertise, supports the expansion of targeted therapy options in these regions.

Segmental Insights

Drug Class Insights

Based on drug class, targeted drugs emerged as the fastest growing segment in 2023. This can be attributed to the numerous advantages it offers, such as its ability to specifically target proteins involved in tumorigenesis. By focusing on specific molecular changes unique to each cancer type, targeted therapy provides a more precise and effective treatment approach. One of the key factors driving the growth of the oncology/cancer drugs market is the minimal adverse effects associated with targeted therapy. The availability of a wide range of targeted therapeutics has also contributed to the market's expansion. The continuous development and innovation in this field are expected to further drive the growth of the oncology drugs market in the coming years.

Route of Administration Insights

Based on the Route of Administration segment, the oral segment dominated the market as oral medications offer a level of convenience that intravenous (IV) or other routes of administration cannot match. Patients can take oral pills or capsules at home, eliminating the need for frequent hospital visits for infusions or injections. This convenience reduces the burden on patients and their caregivers and can lead to better treatment adherence. For many cancer patients, oral drugs can enhance their overall quality of life. They allow individuals to maintain their daily routines, continue working, and enjoy a greater sense of normalcy during treatment, as they do not require prolonged hospital stays.

Regional Insights

In 2023, North America emerged as the leading contributor to revenue, and this trend is expected to continue its dominance. This can be attributed to several factors, including the presence of a large patient population, a strong presence of key players in the healthcare industry, easy availability of drugs, a well-developed healthcare infrastructure, favorable reimbursement policies, a higher number of research, development, and innovation activities, and a greater adoption of advanced therapeutics.

Key Market Players

Astellas Pharma Inc.

Pfizer, Inc.

Novartis AG

Astrazeneca Plc

Merck & Co., Inc.

F. Hoffmann-La Roche Ltd.

Amgen, Inc.

Bristol-Myers Squibb Company

Abbvie Inc.

Johnson & Johnson

Report Scope:

In this report, the Global Oncology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oncology Drugs Market, By Drug Class:

Cytotoxic Drugs Targeted Drugs Hormonal Drugs Others

Oncology Drugs Market, By Route of Administration:

Oral Parenteral Others

Oncology Drugs Market, By Distribution Channel:

Hospital Pharmacies Retail Pharmacies Others

Oncology Drugs Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oncology Drugs Market.

Available Customizations:

Global Oncology Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oncology Drugs Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Drug Class (Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others)
- 5.2.2. By Route of Administration (Oral, Parenteral, Others)
- 5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
- 5.2.4. By Region
- 5.2.5. By Company (2023)
5.3. Market Map

6. North America Oncology Drugs Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Drug Class
- 6.2.2. By Route of Administration
- 6.2.3. By Distribution Channel
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Oncology Drugs Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Drug Class
    - 6.3.1.2.2. By Route of Administration
    - 6.3.1.2.3. By Distribution Channel
- 6.3.2. Canada Oncology Drugs Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Drug Class
    - 6.3.2.2.2. By Route of Administration
    - 6.3.2.2.3. By Distribution Channel
- 6.3.3. Mexico Oncology Drugs Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Drug Class
    - 6.3.3.2.2. By Route of Administration
    - 6.3.3.2.3. By Distribution Channel

7. Europe Oncology Drugs Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Drug Class
- 7.2.2. By Route of Administration
- 7.2.3. By Distribution Channel
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Oncology Drugs Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Drug Class
    - 7.3.1.2.2. By Route of Administration
    - 7.3.1.2.3. By Distribution Channel
- 7.3.2. United Kingdom Oncology Drugs Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Drug Class
    - 7.3.2.2.2. By Route of Administration
    - 7.3.2.2.3. By Distribution Channel
- 7.3.3. Italy Oncology Drugs Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecasty
    - 7.3.3.2.1. By Drug Class
    - 7.3.3.2.2. By Route of Administration
    - 7.3.3.2.3. By Distribution Channel
- 7.3.4. France Oncology Drugs Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Drug Class
    - 7.3.4.2.2. By Route of Administration
    - 7.3.4.2.3. By Distribution Channel
- 7.3.5. Spain Oncology Drugs Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Drug Class
    - 7.3.5.2.2. By Route of Administration
    - 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Oncology Drugs Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Drug Class
- 8.2.2. By Route of Administration
- 8.2.3. By Distribution Channel
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Oncology Drugs Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Drug Class
    - 8.3.1.2.2. By Route of Administration
    - 8.3.1.2.3. By Distribution Channel
- 8.3.2. India Oncology Drugs Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Drug Class
    - 8.3.2.2.2. By Route of Administration
    - 8.3.2.2.3. By Distribution Channel
- 8.3.3. Japan Oncology Drugs Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Drug Class
    - 8.3.3.2.2. By Route of Administration
    - 8.3.3.2.3. By Distribution Channel
- 8.3.4. South Korea Oncology Drugs Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Drug Class
    - 8.3.4.2.2. By Route of Administration
    - 8.3.4.2.3. By Distribution Channel
- 8.3.5. Australia Oncology Drugs Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Drug Class
    - 8.3.5.2.2. By Route of Administration
    - 8.3.5.2.3. By Distribution Channel

9. South America Oncology Drugs Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Drug Class
- 9.2.2. By Route of Administration
- 9.2.3. By Distribution Channel
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Oncology Drugs Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Drug Class
    - 9.3.1.2.2. By Route of Administration
    - 9.3.1.2.3. By Distribution Channel
- 9.3.2. Argentina Oncology Drugs Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Drug Class
    - 9.3.2.2.2. By Route of Administration
    - 9.3.2.2.3. By Distribution Channel
- 9.3.3. Colombia Oncology Drugs Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Drug Class
    - 9.3.3.2.2. By Route of Administration
    - 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Oncology Drugs Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Drug Class
- 10.2.2. By Route of Administration
- 10.2.3. By Distribution Channel
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Oncology Drugs Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Drug Class
    - 10.3.1.2.2. By Route of Administration
    - 10.3.1.2.3. By Distribution Channel
- 10.3.2. Saudi Arabia Oncology Drugs Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Drug Class
    - 10.3.2.2.2. By Route of Administration
    - 10.3.2.2.3. By Distribution Channel
- 10.3.3. UAE Oncology Drugs Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Drug Class
    - 10.3.3.2.2. By Route of Administration
    - 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. Porters Five Forces Analysis

13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products

14. Competitive Landscape

14.1. Astellas Pharma Inc.
- 14.1.1. Business Overview
- 14.1.2. Company Snapshot
- 14.1.3. Products & Services
- 14.1.4. Financials (As Reported)
- 14.1.5. Recent Developments
- 14.1.6. Key Personnel Details
- 14.1.7. SWOT Analysis
14.2. Pfizer, Inc.
14.3. Novartis AG
14.4. Astrazeneca Plc
14.5. Merck & Co., Inc.
14.6. F. Hoffmann-La Roche Ltd.
14.7. Amgen, Inc.
14.8. Bristol-Myers Squibb Company
14.9. Abbvie Inc.
14.10. Johnson & Johnson